Pharming Group Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Pharming Group han disminuido a una tasa media anual de -38.4%, mientras que en la industria Biotechs los beneficios crecieron en un 17.7% anualmente. Los ingresos han ido creciendo a una tasa media de 5.1% al año.

Información clave

-38.4%

Tasa de crecimiento de los beneficios

-39.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	14.8%
Tasa de crecimiento de los ingresos	5.1%
Rentabilidad financiera	-4.8%
Margen neto	-4.3%
Próxima actualización de resultados	08 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12

Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?

Mar 15

Pharming Group (AMS:PHARM) Seems To Use Debt Rather Sparingly

Feb 15

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Pharming Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

ENXTAM:PHARM Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	245	-11	175	69
30 Sep 23	219	-22	160	68
30 Jun 23	206	-16	157	60
31 Mar 23	202	-2	140	53
31 Dec 22	206	14	127	53
30 Sep 22	204	30	110	69
30 Jun 22	202	21	100	70
31 Mar 22	202	11	94	70
31 Dec 21	199	16	91	65
30 Sep 21	200	22	88	48
30 Jun 21	200	31	83	44
31 Mar 21	202	37	79	41
31 Dec 20	212	38	76	39
30 Sep 20	212	44	75	33
30 Jun 20	202	46	70	32
31 Mar 20	202	42	69	33
01 Jan 20	189	41	66	33
30 Sep 19	175	38	58	38
30 Jun 19	175	34	60	36
31 Mar 19	158	29	55	32
31 Dec 18	155	29	54	33
30 Sep 18	152	-29	56	27
30 Jun 18	138	-44	53	25
31 Mar 18	128	-80	53	24
31 Dec 17	108	-91	45	22
30 Sep 17	76	-53	32	21
30 Jun 17	47	-47	21	20
31 Mar 17	31	-21	13	17
31 Dec 16	17	-18	8	16
30 Sep 16	12	-16	6	17
30 Jun 16	12	-15	6	16
31 Mar 16	13	-14	6	17
31 Dec 15	12	-11	5	15
30 Sep 15	29	8	6	14
30 Jun 15	27	9	5	14
31 Mar 15	23	10	4	13
31 Dec 14	26	-7	4	14
30 Sep 14	6	-29	3	15
30 Jun 14	6	-35	3	14
31 Mar 14	11	-35	3	15
31 Dec 13	9	-21	3	14
30 Sep 13	19	-15	3	18
30 Jun 13	18	-19	3	20

Ingresos de calidad: PHARM actualmente no es rentable.

Margen de beneficios creciente: PHARM actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: PHARM no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 38.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de PHARM en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: PHARM no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-14.4%).

Rentabilidad financiera

Alta ROE: PHARM tiene una rentabilidad financiera negativa (-4.82%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Pharming Group Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Recent updates

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 140%

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Price target increased by 8.9% to €1.83

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Now 20% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings: EPS exceeds analyst expectations

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Price target increased to €13.52

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

High number of new directors

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Consensus revenue estimates fall by 14%

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €1.80

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome

Now 21% undervalued after recent price drop

Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe

Consensus forecasts updated

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST®

Price target increased to €10.75

Second quarter 2021 earnings released: EPS €0.008 (vs €0.016 in 2Q 2020)

Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Desglose de ingresos y gastos
Beta